Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology test… Read more
Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) - Total Assets
Latest total assets as of September 2025: $90.98 Billion USD
Based on the latest financial reports, Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) holds total assets worth $90.98 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shin Nippon Biomedical Laboratories, Ltd. - Total Assets Trend (2020–2025)
This chart illustrates how Shin Nippon Biomedical Laboratories, Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shin Nippon Biomedical Laboratories, Ltd. - Asset Composition Analysis
Current Asset Composition (March 2025)
Shin Nippon Biomedical Laboratories, Ltd.'s total assets of $90.98 Billion consist of 35.6% current assets and 64.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.0% |
| Accounts Receivable | $6.64 Billion | 7.2% |
| Inventory | $12.62 Billion | 13.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $219.13 Million | 0.2% |
| Goodwill | $1.88 Billion | 2.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Shin Nippon Biomedical Laboratories, Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shin Nippon Biomedical Laboratories, Ltd.'s current assets represent 35.6% of total assets in 2025, an increase from 31.8% in 2020.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, down from 13.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 13.7% of total assets.
Shin Nippon Biomedical Laboratories, Ltd. Competitors by Total Assets
Key competitors of Shin Nippon Biomedical Laboratories, Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩42.32 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$3.10 Billion |
Shin Nippon Biomedical Laboratories, Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shin Nippon Biomedical Laboratories, Ltd. generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shin Nippon Biomedical Laboratories, Ltd. generates $5.33 in net profit.
Shin Nippon Biomedical Laboratories, Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 1.18 | 1.27 |
| Quick Ratio | 0.66 | 0.69 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.92 Billion | $ 5.14 Billion | $ 4.89 Billion |
Shin Nippon Biomedical Laboratories, Ltd. - Advanced Valuation Insights
This section examines the relationship between Shin Nippon Biomedical Laboratories, Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | $92.42 Billion |
| Market Capitalization | $38.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shin Nippon Biomedical Laboratories, Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shin Nippon Biomedical Laboratories, Ltd.'s assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shin Nippon Biomedical Laboratories, Ltd. (2020–2025)
The table below shows the annual total assets of Shin Nippon Biomedical Laboratories, Ltd. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $92.42 Billion | +21.12% |
| 2024-03-31 | $76.30 Billion | +33.30% |
| 2023-03-31 | $57.24 Billion | +45.61% |
| 2022-03-31 | $39.31 Billion | +6.33% |
| 2021-03-31 | $36.97 Billion | -5.20% |
| 2020-03-31 | $39.00 Billion | -- |